The project, funded under the ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program, seeks to transcend existing limitations in the treatment of lymphatic disorders. Lymphatic vessels, a critical yet often ignored component of the circulatory and immune systems, maintain fluid homeostasis and immune surveillance. Dysfunction in this system leads to progressive and sometimes life-threatening conditions, with lymphedema causing chronic swelling, tissue fibrosis, infection susceptibility, and significant patient morbidity. Currently, no approved therapies exist that regenerate damaged lymphatic tissues or restore normal physiological function.

Central to this research is a novel regenerative therapy termed ELIXIR (Eliminating Lymphatic Irregularities by Cross-disciplinary Intelligent Regulation), designed to reconstruct degenerated lymphatic vessels. The therapy leverages engineered human retinal pigment epithelial cells, already FDA-approved for treating degenerative eye diseases, encapsulated within a protective hydrogel matrix. This hydrogel serves a dual purpose: shielding the cells from the host immune system while maintaining their viability and function. The use of retinal pigment epithelial cells is a strategic choice, capitalizing on their established clinical safety profile and intrinsic regenerative properties.

The ELIXIR system incorporates sophisticated genetic circuitry engineered within the implanted cells. These circuits are activated selectively by externally administered small-molecule regulators, granting clinicians precise temporal and dosage control over therapeutic protein production. This programmable element fosters a sustained, localized reparative environment within the subcutaneous injection site, obviating the need for repeated interventions and allowing for patient-specific treatment modulation. This approach innovatively combines cell therapy, gene engineering, and biomaterials science to realize a first-of-its-kind injectable regenerative medicine.

Initial preclinical trials have demonstrated remarkable efficacy, exhibiting complete lymphatic vessel regeneration directed toward healthy lymph nodes as well as an 80% reduction in edema in large animal models. These promising results substantiate the potential of ELIXIR to reverse structural and functional damage fundamentally, moving beyond symptomatic management to address underlying pathology. Ongoing studies continue to validate the scalability, safety, and therapeutic durability of this paradigm-shifting technology.

The broader significance of ARPA-H’s investment extends beyond lymphedema. By establishing proof of concept for programmable living therapies, this research could inaugurate a new era in the treatment of a spectrum of diseases characterized by structural and immune dysfunction. The platform technology could be adapted to target various chronic and rare disorders, suggesting transformative implications for regenerative medicine and bioengineering.

The current landscape for lymphedema patients is bleak; treatments consist mainly of compression therapy and manual lymph drainage, which require lifelong adherence and yield inconsistent outcomes. The chronic progression of lymphedema increases healthcare burdens exponentially, with annual national costs reaching billions of dollars. ELIXIR represents a paradigm shift by offering a feasible, one-time outpatient treatment projected at a cost between $5,000 and $10,000 per patient—significantly reducing the economic and quality-of-life burdens associated with the disease.

This multidisciplinary project exemplifies a synergistic collaboration, involving Rice University’s sophisticated translational infrastructure and biotechnological incubators such as RBL LLC and the Rice Biotech Launch Pad. The latter bridges gaps between academic discovery and clinical application, accelerating the journey from bench to bedside. The biotech spinout SteerBio Inc., led by CEO Martha Fowler and scientific co-founder Veiseh, is spearheading clinical development and commercialization efforts in partnership with clinical leaders from The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital/Baylor College of Medicine.

Over the next five years, the research team aims to transition ELIXIR from preclinical animal testing to its first-in-human feasibility trial. Success metrics include demonstrable restoration of lymphatic function and progression toward FDA Investigational New Drug application clearance. The work is bolstered by private investment aligned with federal funding to support manufacturing scale-up, regulatory compliance, and equitable patient access, underscoring a comprehensive pathway for translational success.

Furthermore, the incorporation of engineered genetic circuits within a living-cell therapy represents a cutting-edge advance in synthetic biology applications to healthcare. This innovation enables real-time control and adaptability of therapeutic delivery, promising enhanced safety and efficacy over traditional biologics. ELIXIR’s design exemplifies next-generation bioengineering where cell therapies are no longer static but dynamically responsive to patient needs, heralding future programmable treatments for complex diseases.

The clinical potential for ELIXIR extends into varied etiologies of lymphatic dysfunction, from congenital lymphatic malformations to secondary lymphedema following oncologic interventions such as breast cancer surgery. This broad applicability highlights the therapy’s versatility and underscores the urgency of addressing lymphatic diseases historically neglected within the medical community. As the lymphatic system’s role in immunity and fluid regulation gains recognition, therapies like ELIXIR could unlock profound new capabilities in regenerative healthcare.

In summary, Omid Veiseh’s team at Rice University is pioneering a transformational regenerative platform with the potential to redefine lymphedema treatment and exemplify the next generation of living medicines. Supported by ARPA-H’s visionary GLIDE initiative, ELIXIR advances the frontiers of bioengineering, synthetic biology, and clinical translation. This groundbreaking research holds promise not only for millions suffering from lymphatic disorders but also for a broader shift toward durable, programmable, and patient-tailored regenerative therapies.

Subject of Research: Regenerative treatment for repairing damaged lymphatic vessels to cure lymphedema.

Article Title: Rice University Leads $18.2 Million ARPA-H Initiative to Develop Programmable Regenerative Therapy for Lymphedema

News Publication Date: March 4, 2026

Web References:

• ARPA-H GLIDE program: https://arpa-h.gov/explore-funding/programs/glide
• Rice Biotech Launch Pad: https://biotechlaunchpad.rice.edu/
• RBL LLC: https://www.rbl-llc.com/

Image Credits: Photo by Jared Jones/Rice University

Keywords: lymphatic system, lymphedema, regenerative medicine, bioengineering, ELIXIR, advanced cell therapies, ARPA-H, GLIDE program, synthetic biology, programmable genetic circuits, hydrogel encapsulation, translational research

At the helm of this ambitious scientific endeavor is Professor Susan Napier Thomas, a distinguished Woodruff Professor at the George W. Woodruff School of Mechanical Engineering and a leading member of the Parker H. Petit Institute of Bioengineering and Bioscience (IBB). Collaborating closely with her long-time colleague and fellow Woodruff Professor J. Brandon Dixon, Thomas has harnessed over a decade of collaborative research experience to engineer novel biomedical solutions aimed explicitly at correcting lymphatic system failure. Their work begins to fill a critical void in biomedical research where lymphatic diseases have been relatively neglected, despite their high prevalence and the profound impact they have on patients’ quality of life.

The lymphatic system, an intricate network responsible for maintaining fluid homeostasis and mediating immune function, operates as a vital conduit for the circulation of lymph—a fluid carrying immune cells and metabolic waste. When this system malfunctions, interstitial fluid accumulates, resulting in discomfort, swelling, and chronic pathology. Unlike cardiovascular diseases that have seen robust scientific exploration and therapeutic development, lymphatic disorders remain understudied, hindering the evolution of curative interventions. Thomas and Dixon’s project aims to reverse this trend by advancing lymphatic bioengineering and therapeutics to the forefront of modern medicine, moving beyond symptomatic care toward disease-modifying strategies.

This cutting-edge initiative benefits from Georgia Tech’s unique confluence of engineering excellence and biomedical innovation, combining mechanistic understanding with technological prowess. By leveraging advanced biomaterials, microfluidic platforms, and targeted drug delivery systems, the research consortium envisions the creation of sophisticated therapeutic modalities capable of restoring lymphatic vessel function and promoting effective lymphangiogenesis. These interventions promise to interrupt disease progression and mitigate the chronic complications that current palliative treatments fail to address.

The broader implications of this ARPA-H funded project extend beyond engineering, highlighting the vital importance of interdisciplinary collaboration within the biomedical sciences. Andrés García, Executive Director of the IBB, underscores how uniting expertise from mechanical engineering, bioengineering, immunology, and clinical sciences fosters novel solutions for lymphatic diseases that have historically been intractable. This synergy accelerates translation from bench to bedside, ensuring that innovative research swiftly moves toward tangible clinical applications, ultimately improving patient outcomes.

Human clinical trials form a pivotal component of the project’s roadmap, with initial studies focusing on rare pediatric lymphatic conditions as well as chronic lymphatic diseases prevalent in adults. This phased approach allows for the nuanced evaluation of therapeutic safety and efficacy, customized to distinct patient populations often underserved in medical research. The prospect of launching early-phase clinical trials demonstrates the project’s maturity and potential to reshape treatment paradigms across a spectrum of lymphatic disorders.

Carolyn Seepersad, Chair of the Woodruff School of Mechanical Engineering, highlights how the project exemplifies Georgia Tech’s leadership in applying engineering principles to solve urgent healthcare challenges. This initiative not only advances cutting-edge biomedical research but also enhances Georgia’s stature as a burgeoning hub for health technology innovation. By fostering such transformative projects, the Institute plays a critical role in accelerating drug discovery, device development, and therapeutic innovation that benefits both regional and global patient populations.

The funded research aligns closely with ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program, spearheaded by Dr. Kimberley Steele. GLIDE’s mission to accelerate breakthroughs in lymphatic disease treatment reflects a new strategic priority in health research, emphasizing the need to address complex biological systems through innovative engineering and pharmacological approaches. By integrating GLIDE’s vision with Georgia Tech’s technological capabilities, the project inherits a strong foundation to pilot disruptive therapies capable of altering the clinical trajectory of lymphatic patients.

More than a funding milestone, this award symbolizes a shift in biomedical research priorities towards the lymphatic system—a critical yet historically overlooked domain. As the project progresses, its successes will likely stimulate renewed interest and investment in lymphatic biology and therapeutics, filling vital gaps in scientific knowledge. Furthermore, this research could catalyze novel diagnostic tools, personalized medicine approaches, and improved clinical protocols that comprehensively address lymphatic disease’s multifaceted nature.

The impact of this endeavor extends beyond the laboratory. It promises profound patient-centered benefits including reduced morbidity, enhanced immune resilience, and improved quality of life for those afflicted. The potential to reverse or halt disease progression stands to transform healthcare delivery by reducing the burden on patients and healthcare systems alike. In essence, the Georgia Tech team’s efforts represent a beacon of hope for millions suffering from lymphatic disorders worldwide, fostering a future where these diseases are no longer a clinical enigma but a manageable condition.

In conclusion, Georgia Tech’s transformative investment in lymphatic disease therapy research exemplifies the power of interdisciplinary innovation grounded in engineering principles. The comprehensive strategy encompasses fundamental mechanistic studies, advanced technology development, and clinical translation, united by a commitment to address a critical unmet medical need. As this groundbreaking project advances, it reinforces the paradigm that engineering and biomedicine, when strategically combined, hold the key to solving some of healthcare’s most stubborn challenges. The journey towards effective lymphatic disease therapies is not only a scientific frontier but a compassionate mission to restore health and dignity to affected individuals.

Subject of Research: Development of novel engineered therapies targeting lymphatic diseases through interdisciplinary biomedical engineering and bioengineering methods.

Article Title: Georgia Tech Secures $21.8 Million ARPA-H Award to Pioneer Groundbreaking Therapies for Lymphatic Disease

News Publication Date: Not explicitly stated in the provided content.

Web References:

• ARPA-H: https://arpa-h.gov/
• Georgia Tech Mechanical Engineering Faculty (Susan Napier Thomas): https://me.gatech.edu/faculty/thomas
• George W. Woodruff School of Mechanical Engineering: https://www.me.gatech.edu/
• Parker H. Petit Institute of Bioengineering and Bioscience: https://research.gatech.edu/bio
• GLIDE Program: https://arpa-h.gov/explore-funding/programs/glide
• Andrés García Faculty Profile: https://www.me.gatech.edu/faculty/garcia
• Carolyn Seepersad Profile: https://www.me.gatech.edu/user/1078

References: This research was funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H) under Agreement No. 1AY2AX000137-01.

Keywords: lymphatic disease, biomedical engineering, lymphatic system, integrative bioengineering, clinical translation, ARPA-H, GLIDE program, lymphangiogenesis, fluid homeostasis, immune health, therapeutic innovation, Georgia Tech